

New anti-Wolbachia drug regimen could reduce treatment times of LF and Oncho to 1-2 weeks

16 March 2017

This week, scientists from the A-WOL Consortium based at the Liverpool School of Tropical Medicine have published a paper entitled 'Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis' in *Scientific Reports*.

The study explored the development of a shorter treatment regimen, resulting in adult filarial worm death (macrofilaricidal), by using the antibiotic drug rifampicin to target Wolbachia. Unlike doxycycline, this regimen could be safely administered to pregnant women and children.

Professor Mark Taylor, Corresponding Author on the paper, said: "The anti-*Wolbachia* strategy has proved to be a paradigm changing therapeutic approach to the treatment of onchocerciasis and [lymphatic filariasis](#). The data in this paper shows that a clinically safe dose of rifampicin can elicit the same result as the standard 4-6-week doxycycline therapy when administered over just 1-2 weeks. What's more that fact that it is also safe for children and during pregnancy means that interventions are more likely to benefit the community as a whole, taking us one step closer to the WHO's ambition to control and eliminate these terrible diseases."

Previously published findings by the authors have shown that a 4-week course of the tetracycline antibiotic, doxycycline, depletes *Wolbachia* populations in onchocerciasis and leads to long-term sterilization and a macrofilaricidal effect, whereas a 3-week course of doxycycline delivers sub-optimal effects.

This treatment regimen would be compatible for use in children and during pregnancy and, because of the shortened duration of administration required, would be more readily

deliverable by health care systems in resource-poor community settings.

More information: Ghaith Aljayoussi et al, Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis, *Scientific Reports* (2017). [DOI: 10.1038/s41598-017-00322-5](https://doi.org/10.1038/s41598-017-00322-5)

Provided by Liverpool School of Tropical Medicine

APA citation: New anti-Wolbachia drug regimen could reduce treatment times of LF and Oncho to 1-2 weeks (2017, March 16) retrieved 9 November 2022 from <https://medicalxpress.com/news/2017-03-anti-wolbachia-drug-regimen-treatment-lf.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.